Preclinical models and human clinical drug trials have historically used male cohorts as the default baseline. This systemic bias has resulted in delayed diagnosis, suboptimal dosage guidelines, and adverse outcomes for women suffering from neurological conditions.
POLICY BRIEF 03
•
Awareness & Education
Closing the Research Gap in Female Neurobiology
Historically underrepresented in clinical neurology trials, women require sex-specific brain research models to ensure effective diagnostic and treatment protocols.
- 9 Min Read
- Dr. Elena Vance, MD, PhD
- Harvard Medical Faculty • 30+ Publications
CLINICAL AUTHOR & REVIEWER
Dr. Elena Vance, MD, PhD
Director of Clinical Neurobiology
“Precision medicine in neurology is impossible without sex-differentiated biological analysis.”
Harvard Medical Faculty • 30+ Publications
Key Summary Takeaways
SUMMARY
- Mandating 50% female representation in clinical neurotrials
- Analyzing estrogen and progesterone receptor expression in neuroprotection
- Publishing sex-disaggregated clinical safety profiles
Expert Insights & Clinical Commentary
In-depth clinical perspectives and neuro-cognitive analysis.
Female neurochemistry exhibits distinct neuroinflammatory and neurovascular responses that necessitate tailored pharmacological dosages.
Scientific References & Citations
- Journal of Neuroscience & Sex Differentiation (2026).
Additional Resources
THE PROGRAM
About H.E.R. Advocacy Recovery & Resilience
H.E.R. Advocacy Recovery & Resilience provides education, resources, and community to support women on their healing journeys.
Healing is Possible
Share This Resource
Share this clinical educational guide with colleagues and communities.
UP NEXT
[hervoice_next_advocacy_badge]
[hervoice_next_advocacy_title]
[hervoice_next_advocacy_excerpt]
Healthy Women
Stronger Communities
“When women’s brain health is prioritized, everyone benefits.”